NASDAQ: CCCCC4 Therapeutics Inc Stock Ownership - Who owns C4 Therapeutics?
Insider buying vs selling
Have C4 Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Scott N. Boyle | Chief Business Officer | 2023-08-30 | 661 | $2.93 | $1.94kSell |
| Jolie Siegel | Chief Legal Officer | 2023-08-30 | 661 | $2.93 | $1.94kSell |
| Stewart Fisher | Chief Scientific Officer | 2023-08-30 | 661 | $2.93 | $1.94kSell |
| Kelly Schick | Chief People Officer | 2023-08-30 | 661 | $2.93 | $1.94kSell |
| Andrew Hirsch | President CEO | 2023-08-30 | 2,205 | $2.93 | $6.46kSell |
| Lauren White | Chief Financial Officer | 2023-08-30 | 661 | $2.93 | $1.94kSell |
| Glenn Dubin | Director | 2023-07-03 | 3,887 | $2.83 | $11.00kBuy |
| Donna Roy Grogan | Director | 2023-07-03 | 4,858 | $2.83 | $13.75kBuy |
| Kenneth Carl Anderson | Director | 2023-07-03 | 3,976 | $2.83 | $11.25kBuy |
| Donna Roy Grogan | Director | 2023-04-03 | 4,298 | $3.20 | $13.75kBuy |
CCCC insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when CCCC insiders and whales buy or sell their stock.
CCCC Shareholders
What type of owners hold C4 Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Marc A. Cohen | 16.89% | 8,308,874 | $15.87M | Insider |
| Wasatch Advisors LP | 14.64% | 7,199,491 | $13.75M | Institution |
| Alain J. Cohen | 12.39% | 6,094,001 | $11.64M | Insider |
| Price T Rowe Associates Inc | 5.75% | 2,828,605 | $5.40M | Institution |
| Soleus Capital Management LP | 5.47% | 2,692,020 | $5.14M | Institution |
| Millennium Management LLC | 4.34% | 2,135,597 | $4.08M | Institution |
| Blackrock Inc | 4.24% | 2,086,563 | $3.99M | Institution |
| Vanguard Group Inc | 3.86% | 1,900,356 | $3.63M | Institution |
| Bain Capital Life Sciences Investors LLC | 3.34% | 1,642,210 | $3.14M | Institution |
| Tcg Crossover Management LLC | 2.60% | 1,276,574 | $2.44M | Institution |
CCCC vs Biotech Stocks
C4 Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.